Adicet Bio Inc. (ACET)
NASDAQ: ACETHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACET stock chart
Technical analysisKey statistics
All statistics- Market cap
- $20.03M
- EPS (TTM)
- -$7.53
- Dividend yield
- None
- 52-week range
- 2.12 – 11.15
- Day range
- 2.12 – 2.53
- Volume / Avg
- 760.37K / 271.05K
- Beta
- —
- Shares outstanding
- 9.36M
52-week range
ACET stock today
Adicet Bio (ACET) closed at $2.14 on Nov 20, down 13.01% (-$0.32), versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 760.37K shares, a sign of unusually heavy trading. Shares are 80.8% below their 52-week high of $11.15, set on Nov 28, 2025 and 0.9% above the 52-week low of $2.12, near the bottom of the past year's range.
ACET is down 74.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.8%. Adicet Bio has posted a net loss over the last twelve months (EPS of -$7.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Adicet Bio
Company profileAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Chen Schor BA, CPA, M.B.A.
- Headquarters
- Boston, MA
- Employees
- 102
- IPO year
- 2018
- Website
- adicetbio.com
Financial highlights
Full financialsAdicet Bio reported a net loss of $116.8 million, compared with a loss of $117.1 million a year earlier. Diluted earnings per share came in at -$16.95.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-116.80M | $-117.12M | $-142.66M | $-69.79M | $-62.00M |
| EPS (diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$34.83+1527.57%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.76 vs $-1.56
- Surprise
- -12.82%
ACET news
All ACET newsAdicet Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs ACET |
| AARDAardvark Therapeutics Inc. | 0.9226 | -7.74% | $20.20M | vs ACET |
| TXMDTherapeuticsMD Inc. | 1.71 | -5.52% | $19.79M | vs ACET |
| IGCIGC Pharma Inc. | 0.168 | -8.70% | $19.60M | vs ACET |
| CPHIChina Pharma Holdings Inc. | 0.4384 | -13.00% | $18.86M | vs ACET |
| COCPCocrystal Pharma Inc. | 0.95 | -2.05% | $18.30M | vs ACET |
| MRKRMarker Therapeutics Inc. | 1.09 | -17.42% | $18.17M | vs ACET |
| CRVOCervoMed Inc. | 1.46 | +9.77% | $22.09M | vs ACET |
Indexes, lists and sector
Adicet Bio stock FAQ
What is Adicet Bio's stock price today?
ACET last traded at $2.14 as of Nov 20, 4:00 PM EST, down 13.01% on the day. Prices are delayed at least 15 minutes.
Does Adicet Bio pay a dividend?
No. Adicet Bio does not currently pay a regular cash dividend.
Who is Adicet Bio's CEO?
Mr. Chen Schor BA, CPA, M.B.A. is the chief executive officer of Adicet Bio Inc., which has about 102 employees.
Has ACET ever split its stock?
Yes. The most recent ACET stock split was a 1-for-16 split on Dec 30, 2025, one of 2 splits on record.
What is the ACET 52-week high?
The 52-week high for ACET is $11.15 and the 52-week low is $2.12. The stock is currently 80.8% below its high.